X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

EMA Forms Quality Control Group To Boost Drug Innovation

Content Team by Content Team
24th November 2022
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

To support innovative approaches for the development, manufacture, and quality control (QC) of medicines, along with new technologies, digitalization, novel materials, and novel devices for patients in the European Union, the European Medicines Agency (EMA) formed the Quality Innovation Expert Group (QIG).

Eight members of the QIG, which was established in September 2022 and reports to the Quality Domain of EMA’s working party organisation, have backgrounds in chemical, biological, and good manufacturing practise (GMP) inspections. The organisation will make sure that the European drug regulatory network maintains its innovative momentum, identifies and fills in regulatory framework gaps, and gives new technology developers more predictability. The group will serve as a forum for discussion and engagement among EU regulators, stakeholders, including academia and industry, and the EU regulatory network, such as the EU Innovation Network. To assist the convergence of worldwide regulatory standards, close coordination with foreign partners will be another goal.

The EMA states that the QIG will do the following to support quality control of medicines:

  • Provide a forum for developers to debate novel approaches to drug development, production, and/or control.
  • Create instructions for cutting-edge production and quality technologies.
  • Participate in training sessions or workshops on pharmaceutical quality for EU evaluators and GMP inspectors.

Identifying novel emerging technologies that are expected to have an impact on regulatory decision-making in the medium to long term is another responsibility, as is developing suitable regulatory reactions in advance as these technologies develop.

The group will contribute to the evaluation of processes used in regulatory submissions that contain these novel technologies, such as scientific recommendations, marketing authorization applications, and pertinent post-authorization lifecycle development.

The regulatory body’s Regulatory Science Strategy to 2025, which outlined important objectives and fundamental suggestions for human pharmaceuticals, will serve as the foundation for the QIG’s activities. These are the strategy’s top five objectives:

  • Promoting the integration of science and technology in the creation of pharmaceuticals
  • Promoting cooperative evidence development and raising the scientific calibre of assessments
  • Partnering with healthcare systems to increase patient-centered access to medications
  • Addressing new risks to health, as well as issues with accessibility and treatment
  • Promoting and making use of regulatory science research and innovation.

Previous Post

Detecting Traces of β-Lactam Antibiotics Using UHPLC-MS-MS

Next Post

Study Bringing Personalised Immunotherapy Therapies Closer

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Study Bringing Personalised Immunotherapy Therapies Closer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In